As per the research report, the size of the Europe Thin Film Drugs market is valued at USD 5.18 billion in 2022 and is expected to reach USD 8.09 billion by 2027 at 9.33% CAGR during the forecast period 2022 to 2027.
The European thin-film drugs market is developing robust business strategies, aiming to influence various users and customers, primarily driving the market. Thin-film drugs are emerged as an alternative to tablets or capsules due to their improved efficacy. The drugs are made from polymers that dissolve quickly when held in the mouth or oral cavity, delivering the drug directly into the body's systemic circulation, especially by sublingual absorption. The bioavailability of a sublingually administered dose is around 35%, with the onset of reaction in 5-10 mins. All these factors increase the popularity of thin film drugs in the pharmaceutical industry.
Oral thin-film drugs provide high patient compliance ease of storage and transport. In addition, they offer precise dosing with the desired effective result. Thus, the thin film drug delivery systems market has been substantially attractive for the past several years. The high level of acceptance and the impressive benefits have further boosted the European thin films drugs market.
Coupled with effective customer-centric strategies will increase the volume of consumers. Furthermore, drivers such as growing demand for efficient drug delivery systems, low cost of manufacturing thin film drugs compared to traditional dosage forms, and increased research to develop new polymeric thin films are predicted to increase the demand for the European market.
In addition, beneficial government initiatives and an increase in the number of pharmaceutical companies are other drivers expected to increase the growth of the Europe thin film drugs market.
However, the European thin film drugs market will be negatively impacted by the high costs of treatment, availability of various alternative drug delivery options, and lack of awareness. In addition, some of the solvents and polymers used in film coating are relatively harmful. Inflammation due to some of the organic solvents used as vehicles for film-forming polymers could present a risk to the patient.
This research report on the Europe Thin Film Drugs Market has been segmented and sub-segmented into the following categories:
By Disease Indication:
By Distribution Channel:
Geographically, the German thin film drugs market is anticipated to grow by around 6.2% CAGR during the forecast period. The presence of a large population of geriatric patients with dysphagia and the increase in healthcare spending will help drive the market in Germany in the coming years. In 2015, just over 4.65 million people in Germany were at least 80 years old. Their number will continue to grow over the next decades and reach around 9.97 million by 2050; this corresponds to a population share of about 13%.
The Spain thin film drugs market is expected to be a lucrative market for thin films drugs during the mentioned period. And the France thin film drugs market is leading the market in the improving awareness, production, and distribution of oral thin-film drugs, which will also help the progress of the Europe thin film drugs market. Furthermore, a large population of geriatric patients focuses on providing other drug delivery options, especially for critical drugs, and more clinical trials in laboratories, medical institutes, and research centers in these countries drive the market in the coming years.
The U.K thin film drugs market accounted for over 55% due to owing to the presence of advanced technologies for pharmaceutical research and development, high investment for the discovery of new drug delivery techniques, and the increasing need for effective drug delivery routes and their stability would further stimulate the market for thin film drugs in Europe.
KEY MARKET PLAYERS
Key players operating in the Europe Thin Film Drugs Market profiled in this report are Pfizer Inc, Wolters Kluwer, Solvay, Allergan plc., MonoSol Rx, IntelGenx Corp., ZIM Laboratories Limited, and IntelGenx Corp, Sumitomo Dainippon Pharma Co. Ltd., Indivior Plc, Novartis AG.,
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.2 Oral Thin Film
126.96.36.199 Sublingual Film
188.8.131.52 Fully Dissolving Dental/Buccal Film
5.1.3 Transdermal Thin Film
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2 Disease Indication
5.2.4 Opioid Dependence
5.2.5 Nausea and Vomiting
5.2.6 Y-o-Y Growth Analysis, By Disease Indication
5.2.7 Market Attractiveness Analysis, By Disease Indication
5.2.8 Market Share Analysis, By Disease Indication
5.3 Distribution Channel
5.3.2 Hospital Pharmacies
5.3.3 Drug Store
5.3.4 Retail Pharmacies
5.3.7 Y-o-Y Growth Analysis, By Distribution Channel
5.3.8 Market Attractiveness Analysis, By Distribution Channel
5.3.9 Market Share Analysis, By Distribution Channel
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
184.108.40.206 By Geographical Area
220.127.116.11 By Product
18.104.22.168 By Disease Indication
22.214.171.124 By Distribution Channel
6.1.4 Market Attractiveness Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By Product
184.108.40.206 By Disease Indication
220.127.116.11 By Distribution Channel
6.1.5 Market Share Analysis
18.104.22.168 By Geographical Area
22.214.171.124 By Product
126.96.36.199 By Disease Indication
188.8.131.52 By Distribution Channel
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Pfizer Inc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Novartis AG
8.3 Wolters Kluwer
8.5 Allergan plc.
8.6 Sumitomo Dainippon Pharma Co. Ltd.
8.7 Indivior Plc.
8.8 MonoSol Rx
8.9 IntelGenx Corp.
8.10 ZIM Laboratories Limited
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.